BC
ALXN

Bartlett & Co’s Alexion Pharmaceuticals ALXN Stock Holding History

Bartlett & Co’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50
Closed -$9K – 1090
2021
Q2 		$9K Hold
50
– – ﹤0.01% 706
2021
Q1 		$8K Hold
50
– – ﹤0.01% 756
2020
Q4 		$8K Hold
50
– – ﹤0.01% 757
2020
Q3 		$6K Hold
50
– – ﹤0.01% 730
2020
Q2 		$6K Hold
50
– – ﹤0.01% 732
2020
Q1 		$4K Buy
+50
New +$4.91K ﹤0.01% 741
2019
Q3 		$5K Hold
50
– – ﹤0.01% 782
2019
Q2 		$7K Hold
50
– – ﹤0.01% 614
2019
Q1 		$7K Hold
50
– – ﹤0.01% 601
2018
Q4 		$5K Hold
50
– – ﹤0.01% 624
2018
Q3 		$7K Hold
50
– – ﹤0.01% 625
2018
Q2 		$6K Hold
50
– – ﹤0.01% 631
2018
Q1 		$6K Hold
50
– – ﹤0.01% 649
2017
Q4 		$6K Buy
+50
New +$6.09K ﹤0.01% 624
2015
Q1 		– Sell
-150
Closed -$28K – 809
2014
Q4 		$28K Buy
+150
New +$27.8K ﹤0.01% 514

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Bartlett & Co's ALXN Position: Q3 2021 in Review

Bartlett & Co sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 50 shares — an estimated $9K sold.

Bartlett & Co first reported a position in ALXN in Q4 2014 and held it in 15 quarters. The position peaked at $28K in Q4 2014. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Bartlett & Co reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Bartlett & Co sold 50 Alexion Pharmaceuticals shares in Q3 2021, an estimated $9K.
  • Bartlett & Co first reported a position in Alexion Pharmaceuticals in Q4 2014 and held it in 15 quarters.
  • Bartlett & Co's Alexion Pharmaceuticals position peaked at $28K in Q4 2014.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Bartlett & Co's 13F filing for Q3 2021, filed 15 Oct 2021.